Key terms
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NRBO news
Mar 13
8:03am ET
NeuroBo Pharmaceuticals cleared to continue Phase 2a trial of DA-1241
Mar 04
8:03am ET
NeuroBo Pharmaceuticals names Marshall Woodworth as CFO
Feb 29
8:08am ET
NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial
Feb 01
8:03am ET
NeuroBo Pharmaceuticals: FDA clears IND application for DA-1726
Jan 18
8:08am ET
NeuroBo announces pre-clinical safety data of DA-1241 with sitagliptin
Jan 09
8:38am ET
NeuroBo Pharmaceuticals regains Nasdaq compliance
Dec 28
9:03am ET
NeuroBo submits IND application to FDA for Phase 1 trial of DA-1726
Dec 20
7:50pm ET
NeuroBo Pharmaceuticals trading halted, news pending
Dec 19
8:46am ET
NeuroBo Pharmaceuticals announces 1-for-8 reverse stock split
No recent news articles are available for NRBO
No recent press releases are available for NRBO
NRBO Financials
Key terms
Ad Feedback
NRBO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NRBO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range